Thirdly, a MAGED2 CRISPR KO-expressing lipofectamine vector was created and transfected into glioma U251-MG cells, allowing it to stably downregulate MAGED2’s expression levels in vitro. Here, MAGED2 is linked to central nervous system cancer.